Anecdotal evidence that patients with cancers with MET fusions may benefit from MET inhibitors comes from a case report of a woman with NSCLC and brain metastases harboring an HLA–DRB1–MET fusion. The gene discussed is MET; the disease is non-small cell lung carcinoma.